Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.
Daniel J GeorgeJean-Francois MartiniMichael StaehlerRobert J MotzerAhmed MagheliFrede DonskovBernard EscudierSherry LiMichelle CaseyOlga ValotaBrigitte LaguerreAllan J PantuckHardev S PandhaAnup PatelMaria LechugaAlain RavaudPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Correlations between VEGFR1 and VEGFR2 SNPs and longer DFS with sunitinib suggest germline SNPs are predictive of improved outcomes with adjuvant sunitinib in patients with renal cell carcinoma. Independent validation studies are needed to confirm these findings.
Keyphrases
- renal cell carcinoma
- phase iii
- open label
- clinical trial
- early stage
- phase ii
- genome wide
- double blind
- vascular endothelial growth factor
- placebo controlled
- dna repair
- gene expression
- study protocol
- case control
- clinical decision support
- adipose tissue
- dna damage
- insulin resistance
- skeletal muscle
- weight loss
- electronic health record